Abstract | BACKGROUND: METHODS: RESULTS: 1.44% (12/836) patients in this study developed peritoneal carcinomatosis and 12 patients with adenocarcinoma had metachronous NSCLC diagnosis and PC. Malignant pleural effusion rates at baseline and at PC diagnosis were separately 50% (6/12) and 100.0% (12/12). Among the 12 patients, 9 patients harbored EGFR/ALK/ROS1 mutation. The outcome of patients with EGFR/ALK/ROS1 mutation was significantly better than that of patients without EGFR/ALK/ROS1 mutation, the mOS1 and mOS2 were separately 26.0 months and 6.0 months versus 10.0 months and 1.5 months (P<0.05). The mOS2 of patients with aggressive treatment after PC diagnosis was 6.0 months, significantly better than 1.0 month of patients with best supportive care (P<0.05). The mOS2 of the patients with angiogenesis inhibitors based-treatment after PC diagnosis was 8.5 months, significantly longer than that of patients with other treatments (P<0.05). CONCLUSIONS:
|
Authors | Baoshan Cao, Yan'e Liu, Wencheng Yin, Qian Li, Li Liang |
Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer
(Zhongguo Fei Ai Za Zhi)
Vol. 22
Issue 3
Pg. 143-150
(Mar 20 2019)
ISSN: 1999-6187 [Electronic] China |
PMID | 30909993
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Carcinoma, Non-Small-Cell Lung
(diagnosis, pathology, therapy)
- Female
- Humans
- Lung Neoplasms
(diagnosis, pathology, therapy)
- Male
- Middle Aged
- Peritoneal Neoplasms
(secondary)
- Prognosis
- Proto-Oncogene Mas
- Retrospective Studies
|